Answers are grounded in this paper and cite their sources.
INTRODUCTION: Respiratory syncytial virus (RSV) is an important cause of lower respiratory tract disease (LRTD) and hospitalization in older adults, individuals with certain chronic medical conditions, and immunocompromised patients. RSV can result in acute and longer-term cardiovascular and respiratory morbidity, and declines in physical functioning and quality of life. AREAS COVERED: Adjuvanted RSVPreF3 was the first RSV vaccine licensed for preventing RSV-LRTD in adults, with initial approvals in 2023 in the United States and Europe. Robust clinical trial data showed an acceptable safety profile and demonstrated efficacy against RSV-LRTD, with exploratory post-hoc analyses suggesting reductions in RSV-related chronic obstructive pulmonary disease (COPD)/asthma exacerbations. These findings are reinforced by real-world evidence showing effectiveness against RSV-related hospitalizations, COPD/asthma exacerbations, and cardiovascular events. EXPERT OPINION: This emerging evidence supports a broader role of adjuvanted RSVPreF3 beyond preventing RSV-LRTD alone to preserve cardiovascular and respiratory health. RSV vaccination should be considered within an integrated routine care and preventive management strategy for older adults and individuals with chronic conditions, alongside other adult immunizations and health interventions. Addressing implementation barriers for adjuvanted RSVPreF3 and emphasizing its role in maintaining health and independence will be critical to enable widespread uptake and help protect patient health.
No takes yet. Share an insight, caveat, or question.
Dezutter et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: